Category Archives: "Partners"

EMD Serono data at CMSC & ACTRIMS Annual Meeting reinforces proven efficacy of rebif
EMD Serono Data at CMSC & ACTRIMS Annual Meeting Reinforces Proven Efficacy of Rebif® (interferon beta-1a) and Demonstrates Continued [...]
Acorda Therapeutics to showcase online multiple sclerosis resources at 2014 CMSC/ACTRIMS meeting
Acorda Therapeutics to Showcase Online Multiple Sclerosis Resources at 2014 CMSC/ACTRIMS Meeting 05/27/2014 The award-winning [...]
Genzyme recognizes sixth annual World MS Day
Genzyme Recognizes Sixth Annual World MS Day - Company Supporting Wide Range of Programs to Help Improve the Lives of People Living with [...]
CHMP adopts positive opinion for PLEGRIDY as a treatment for multiple sclerosis in the EU
CHMP Adopts Positive Opinion for PLEGRIDYâ„¢ (Peginterferon Beta-1a) as a Treatment for Multiple Sclerosis in the European Union Friday, [...]
Teva announces COPAXONE recognized as “Brand of the Year” by Pharm Exec Magazine
Teva announces COPAXONE® recognized as Brand of the Year by Pharmaceutical Executive Magazine JERUSALEM--(BUSINESS WIRE)--May 8, [...]
New TYSABRI analysis shows improved walking speed in significant number of multiple sclerosis patients
New TYSABRI® Analysis at AAN Annual Meeting Shows Improved Walking Speed in Significant Number of MS Patients Thursday, May 1, 2014 [...]
New data reinforce efficacy of TECFIDERA in multiple sclerosis patients with high disease activity
New Data Reinforce Efficacy of TECFIDERA® (Dimethyl Fumarate) in MS Patients with High Disease Activity Wednesday, April 30, 2014 7:30 [...]
A farewell tribute to Mike Robinson – President, National Multiple Sclerosis Society of Zimbabwe
A Farewell Tribute to Mike Robinson – President, Multiple Sclerosis Society of Zimbabwe   POET AND SALUTATION DEDICATION: MR. [...]
Slowing of brain atrophy sustained at three years in patients treated with Lemtrada
Slowing of Brain Atrophy and Reductions in New Multiple Sclerosis Lesions Sustained at Three Years in Patients Treated with Genzyme’s [...]
Genzyme announces multi-year multiple sclerosis research collaboration with academic medical center
Genzyme Announces Multi-Year Multiple Sclerosis Research Collaboration with Leading Academic Medical Center Wednesday, April 30, 2014 [...]
  • (201) 487-1050
  • 3 University Plz Dr Ste 116, Hackensack, NJ 07601
  • info@mscare.org

Upcoming Testing Periods

WINTER 2024 TESTING PERIOD

Application Deadline: December 6th, 2023

First Day of Testing: Saturday, January 6th, 2024

Last Day of Testing: Saturday, January 20th, 2024

SUMMER 2024 TESTING PERIOD

Application Deadline: May 1st, 2024

First Day of Testing: Saturday, June 1st, 2024

Last Day of Testing: Saturday, June 15th, 2024

Resources

Visit PTC to download a PDF version of the Handbook. Candidates can also apply online.

For more information:

Professional Testing Corporation http://www.ptcny.com/

  • 212-356-0660
  • 1350 Broadway, 17th Floor, New York, NY 10018

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us





I have a question about

First

Last




Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM